Dong Kim - Mar 25, 2022 Form 3 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Financial Officer
Signature
/s/ Jason Smith, Attorney-in-Fact
Stock symbol
URGN
Transactions as of
Mar 25, 2022
Transactions value $
$0
Form type
3
Date filed
3/29/2022, 07:11 PM
Next filing
Feb 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding URGN Ordinary Shares 31.9K Mar 25, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding URGN Employee Stock Option (right to buy) Mar 25, 2022 Ordinary Shares 10K $11.92 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One third of the shares underlying the stock option will vest on each of December 1, 2022, December 1, 2023 and December 1, 2024.